Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction

A Jagerschmidt, N Guillaume, N Goudreau, B Maigret and BP Roques

Departement de Pharmacochimie Moleculaire et Structurale U266 INSERM, Universite Rene Descartes, Paris, France.

We examined the functional significance of two residues present in the second (Asp100) and seventh (Asn391) transmembrane domains of the rat cholecystokininB (CCKB) receptor that are highly conserved among the members of the G protein-coupled receptor family. Substitution of Asn for Asp100 by using site-directed mutagenesis did not change the affinity and selectivity for agonists but slightly increased the affinity of three CCKB-selective antagonists of different chemical structures. Cells expressing the mutant receptor exhibited a 50% reduction in CCKB-induced phosphoinositide turnover compared with cells expressing the wild-type receptor, suggesting a critical role for this residue in the coupling of the CCKB receptor to G protein. This latter was shown to be insensitive to pertussis toxin treatment and could therefore belong to the Gq family. Replacement of Asn391 by Asp located in the seventh transmembrane domain did not change agonist binding or phosphoinositide turnover. This suggests that in contrast to the gonadotropin-releasing hormone receptor, there is no direct interaction in the CCKB receptor between Asp100 and Asn391. However, a rhodopsin- based molecular modeling of the CCKB receptor showed a spatial proximity between Asp100 and the carboxyl terminal part of the third intracellular loop, known to interact with G protein. This could explain the reduction in phosphoinositide turnover observed with the Asn100 mutant.

Volume 48, Issue 5, pp. 783-789, 11/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF]

				P.-Y. Deng and S. Lei Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats J. Physiol., April 15, 2006; 572(2): 425 - 442. [Abstract] [Full Text] [PDF]

				C. Gales, M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies Mol. Pharmacol., May 1, 2003; 63(5): 973 - 982. [Abstract] [Full Text] [PDF]

				F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]

				C. A. Flanagan, W. Zhou, L. Chi, T. Yuen, V. Rodic, D. Robertson, M. Johnson, P. Holland, R. P. Millar, H. Weinstein, et al. The Functional Microdomain in Transmembrane Helices 2 and 7 Regulates Expression, Activation, and Coupling Pathways of the Gonadotropin-releasing Hormone Receptor J. Biol. Chem., October 8, 1999; 274(41): 28880 - 28886. [Abstract] [Full Text] [PDF]

				J. P. Roche, S. Bounds, S. Brown, and K. Mackie A Mutation in the Second Transmembrane Region of the CB1 Receptor Selectively Disrupts G Protein Signaling and Prevents Receptor Internalization Mol. Pharmacol., September 1, 1999; 56(3): 611 - 618. [Abstract] [Full Text]

				A. Jagerschmidt, N. Guillaume, B. P. Roques, and F. Noble Binding Sites and Transduction Process of the CholecystokininB Receptor: Involvement of Highly Conserved Aromatic Residues of the Transmembrane Domains Evidenced by Site-Directed Mutagenesis Mol. Pharmacol., May 1, 1998; 53(5): 878 - 885. [Abstract] [Full Text]

				Z. Ji, E. M. Hadac, R. M. Henne, S. A. Patel, T. P. Lybrand, and L. J. Miller Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling J. Biol. Chem., September 26, 1997; 272(39): 24393 - 24401. [Abstract] [Full Text] [PDF]

				S. C. Sealfon, H. Weinstein, and R. P. Millar Molecular Mechanisms of Ligand Interaction with the Gonadotropin-Releasing Hormone Receptor Endocr. Rev., April 1, 1997; 18(2): 180 - 205. [Abstract] [Full Text]

				K. Kennedy, V. Gigoux, C. Escrieut, B. Maigret, J. Martinez, L. Moroder, D. Frehel, D. Gully, N. Vaysse, and D. Fourmy Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin J. Biol. Chem., January 31, 1997; 272(5): 2920 - 2926. [Abstract] [Full Text] [PDF]

				C. Gales, A. Kowalski-Chauvel, M. N. Dufour, C. Seva, L. Moroder, L. Pradayrol, N. Vaysse, D. Fourmy, and S. Silvente-Poirot Mutation of Asn-391 within the Conserved NPXXY Motif of the Cholecystokinin B Receptor Abolishes Gq Protein Activation without Affecting Its Association with the Receptor J. Biol. Chem., June 2, 2000; 275(23): 17321 - 17327. [Abstract] [Full Text] [PDF]